Archive | May, 2010

Genetic Testing Gets a Boost From Medco(MHS)

Diagnostic Medicine is on the Forefront Genetic tests and the new field of pharmacogenomics is getting marketing support from an unlikely source-Pharmacy Benefit Managers (PBM’s). Medco (MHS), a $60B revenue PBM ($26B Market Cap)with over 65M members has been developing a strategy for “personalized medicine” backed by recent acquisitions and partnerships with the Mayo Clinic […]

Continue Reading 0

Pathway Genomics Makes Giant Marketing Step in Personalized Medicine

Genotyping on a Fast Track Direct to Consumer Pathway Genomics is offering a “Health Kit” that reports your genetic risk for 70 diseases such as Cancer,Cardiovascular Disease,RA,and Diabetes. Disease carrier status is included as well as potential genetic interactions with commonly used medications such as Coumadin, Statins and Plavix. A “Saliva Collection Kit” will be […]

Continue Reading 0

Response Genetics(RGDX) Signs Agreement with Glaxo for BRAF Gene

Response Genetics(RGDX) announced a deal today for a non-exclusive license to provide GlaxoSmithKline (GSK) with certain rights to proprietary BRAF mutational analysis technology in human tumor samples. The BRAF gene encodes a protein involved in cell signaling and cellular growth and differentiation.Specific gene mutations have been correlated with the development of certain forms of cancer. […]

Continue Reading 0

Biomarkers Drive Personalized Medicine

Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche, is a nascent paradigm for exploiting breakthroughs in the molecular basis of disease and more targeted […]

Continue Reading 0